The lowest median SLFN11 expressors were colon and prostate cancers, the highest were kidney and head and neck cancers (Fig. 1b, c), and these findings corroborated with prevalence studies in patient-derived-xenograft models [11] and clinical samples [12, 25]. This evidence concerns the gene SLFN11 and head and neck cancer.